Product logins

Find logins to all Clarivate products below.


Hypertension | Current Treatment: Physician Insights | US | 2020

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different classes. Nevertheless, despite the numerous treatment options, significant unmet need remains in the treatment of resistant hypertension, which is defined as inadequately controlled BP despite the concurrent use of three or more antihypertensive agents. This report provides cardiologist insight into prescribing patterns for hypertension and especially resistant hypertension.

Questions Answered:

  • What patient shares do angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) garner in the U.S. hypertension market? What are the trends in prescribing for resistant hypertension?
  • How do physicians diagnose resistant hypertension, and how does this diagnosis influence their treatment approach?
  • What factors constrain and what factors drive choice of hypertension treatment?
  • What percentage of hypertensive patients receive monotherapy versus combination therapy?

Product Description:

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

GEOGRAPHY: United States

PRIMARY RESEARCH: Survey of 100 U.S. cardiologists

KEY DRUGS COVERED: ACE inhibitors, ARBs, diuretics, calcium channel blockers, beta blockers, aldosterone antagonists, mineralocorticoid receptor antagonists (MRAs), diuretics, direct renin inhibitors, centrally acting antihypertensives, and alpha blockers.

KEY INSIGHTS PROVIDED: Factors influencing disease management and treatment decisions; drivers of and constraints on treatment selection; physician-reported treatment practices; rationale for changes in treatment approach; physician insight on persistency and compliance; physician-reported recent/anticipated changes in treatment approach.

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…